The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study

Overview

Journal J Gastric Cancer

Date 2018 Apr 10

PMID 29629220

Citations 15

Authors

Sung Ho Jang

Young Jae Jung

Min Gyu Kim

Sung Joon Kwon

Affiliations

Soon will be listed here.

Abstract

Purpose: Postoperative adjuvant chemotherapy is usually prescribed to improve the survival of patients with advanced gastric cancer who undergo curative surgery. This study was designed to determine the impact that the degree of compliance with chemotherapy has on the prognosis of patients with gastric cancer.

Materials And Methods: Among 252 patients with stage III gastric cancer who underwent curative surgery between July 2004 and December 2014, 85 patients were postoperatively treated with S-1, the oral fluoropyrimidine derivative, 23 received no chemotherapy, and 144 received other regimens. Overall survival was compared between the complete compliance group (who received 8 cycles of S-1 chemotherapy, n=44) and the incomplete compliance group (who received less than 8 cycles of S-1 chemotherapy, n=41). Factors that influenced patient compliance with chemotherapy were also analyzed.

Results: The overall 5-year survival rate was significantly different between the complete chemotherapy and incomplete chemotherapy groups (80.0% vs. 42.7%, P<0.001). Based on univariate and multivariate survival analyses of patients who received S-1 chemotherapy, the independent prognostic factors were tumor, node, and metastasis (TNM) stage (IIIa vs. IIIb vs. IIIc) and compliance with chemotherapy. TNM stage and age are significant factors that influence compliance with chemotherapy.

Conclusions: TNM stage and compliance with chemotherapy are independent prognostic factors in patients with stage III gastric cancer who received postoperative chemotherapy. TNM stage and age are significant factors that influence patient compliance with chemotherapy.

Citing Articles

Advantages of adjuvant chemotherapy using S-1 following minimally invasive gastrectomy for gastric cancer versus open surgery: a propensity score-matched analysis.

Ri M, Nishie N, Ohashi M, Fukuoka S, Yamaguchi K, Makuuchi R Gastric Cancer. 2024; 28(1):122-130.

PMID: 39509007 DOI: 10.1007/s10120-024-01565-8.

Nomogram to predict overall survival of patients receiving radical gastrectomy and incomplete peri-operative adjuvant chemotherapy for stage II/III gastric cancer: a retrospective bi-center cohort study.

Liu D, Quan H, Ma M, Zhou H, Yang X, Wu Z BMC Cancer. 2024; 24(1):344.

PMID: 38500085 PMC: 10946121. DOI: 10.1186/s12885-024-12103-1.

Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide Study.

Tsekrekos A, Borg D, Johansson V, Nilsson M, Klevebro F, Lundell L Ann Surg Oncol. 2023; 30(12):7196-7205.

PMID: 37505355 PMC: 10562295. DOI: 10.1245/s10434-023-13967-6.

Jin G, Park K, Song K Korean J Clin Oncol. 2023; 17(1):31-36.

PMID: 36945212 PMC: 9942746. DOI: 10.14216/kjco.21005.

Nutritional Status Indicators Affecting the Tolerability of Postoperative Chemotherapy After Total Gastrectomy in Patients With Gastric Cancer.

Toyota K, Mori M, Hirahara S, Yoshioka S, Kubota H, Yano R J Gastric Cancer. 2022; 22(1):56-66.

PMID: 35425654 PMC: 8980594. DOI: 10.5230/jgc.2022.22.e5.

References

Fuentes E, Ahmad R, Hong T, Clark J, Kwak E, Rattner D . Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg. 2015; 20(1):172-9. DOI: 10.1007/s11605-015-2954-5. View

Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R . Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol. 2016; 8(5):439-49. PMC: 4865711. DOI: 10.4251/wjgo.v8.i5.439. View

Eun H, Hur H, Byun C, Son S, Han S, Cho Y . Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. J Gastric Cancer. 2015; 15(2):113-20. PMC: 4496437. DOI: 10.5230/jgc.2015.15.2.113. View

Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S . Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008; 100(6):388-98. DOI: 10.1093/jnci/djn054. View

Fujitani K, Yang H, Mizusawa J, Kim Y, Terashima M, Han S . Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17(3):309-318. DOI: 10.1016/S1470-2045(15)00553-7. View

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

Yamashita K, Kurokawa Y, Yamamoto K, Hirota M, Kawabata R, Mikami J . Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study. Ann Surg Oncol. 2017; 24(9):2639-2645. DOI: 10.1245/s10434-017-5923-2. View

Zhao S, Fang J . The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest. 2008; 26(3):317-25. DOI: 10.1080/07357900701834686. View

Imamura H, Kishimoto T, Takiuchi H, Kimura Y, Morimoto T, Imano M . Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother. 2013; 26(1):57-61. DOI: 10.1179/1973947813Y.0000000116. View

10.

Allum W, Blazeby J, Griffin S, Cunningham D, Jankowski J, Wong R . Guidelines for the management of oesophageal and gastric cancer. Gut. 2011; 60(11):1449-72. DOI: 10.1136/gut.2010.228254. View

11.

Miceli R, Tomasello G, Bregni G, Di Bartolomeo M, Pietrantonio F . Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol. 2014; 20(16):4516-25. PMC: 4000488. DOI: 10.3748/wjg.v20.i16.4516. View

12.

Wagner A, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J . Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3):CD004064. DOI: 10.1002/14651858.CD004064.pub3. View

13.

Lee J, Kim J, Jung H, Kim J, Jeong W, Jeon T . Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014; 14(2):87-104. PMC: 4105383. DOI: 10.5230/jgc.2014.14.2.87. View

14.

Saif M, Makrilia N, Zalonis A, Merikas M, Syrigos K . Gastric cancer in the elderly: an overview. Eur J Surg Oncol. 2010; 36(8):709-17. DOI: 10.1016/j.ejso.2010.05.023. View

15.

Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T . Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer. 2012; 16(2):133-9. DOI: 10.1007/s10120-012-0158-1. View

16.

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View

17.

Aoyama T, Sato T, Maezawa Y, Kano K, Hayashi T, Yamada T . Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. Int J Clin Oncol. 2017; 22(3):476-483. DOI: 10.1007/s10147-017-1089-y. View

18.

Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N . Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. Gastric Cancer. 2013; 17(2):383-6. DOI: 10.1007/s10120-013-0264-8. View

19.

Foo M, Leong T . Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol. 2014; 20(38):13718-27. PMC: 4194555. DOI: 10.3748/wjg.v20.i38.13718. View

20.

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T . Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29(33):4387-93. DOI: 10.1200/JCO.2011.36.5908. View